Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Guardant Health Jumped Higher on Friday

By Brian Orelli, PhD - Feb 29, 2020 at 1:21PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It was a roller coaster of a week for the cancer test maker.

What happened

Shares of Guardant Health (GH -0.52%) jumped 12.7% on Friday for no apparent reason. Shares of the test maker have been on a roller coaster this week: down on Tuesday after the company reported fourth-quarter results, and back up on Wednesday.

With the broader market down this week, Friday's move could be that investors are fleeing to companies that are less likely to be hurt by the COVID-19 coronavirus outbreak.

So what

Guardant Health sells its Guardant360 test for patients with advanced cancer to profile their tumors through a simple blood test and identify genetic alterations in the tumor that doctors can exploit with medications specific for that type of tumor. Cancer patients are still going to be tested even if the COVID-19 outbreak becomes more widespread.

The healthcare company also has a test called GuardantOMNI, which analyzes significantly more potential mutations and is used by pharmaceutical companies in their clinical trials. Again, those studies aren't likely to be shut down if COVID-19 spreads throughout the U.S. as the patients are still going to need treatment.

Doctor working at a computer

Image source: Getty Images.

Now what

It should be noted that through the roller coaster of a week, Guardant Health ended the week down about 2%, which seems reasonable given the fairly solid fourth-quarter results.

Guidance for this year is for revenue in the range of $275.0 million to $285.0 million, up 31% year over year at the midpoint and higher than the analyst consensus estimate of $273.1 million.

The loss this year may be more than investors were expecting, but as fellow Fool Keith Speights noted, the company is investing in the future through its LUNAR program for the early detection of cancer and recurrence monitoring, which should payoff in years to come.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Guardant Health, Inc. Stock Quote
Guardant Health, Inc.
GH
$42.04 (-0.52%) $0.22

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
319%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.